# THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

Study · id `cardio:ct-nct06559891` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06559891](<https://clinicaltrials.gov/study/NCT06559891>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06559891

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 261 participants.

## Technical summary

Registry record NCT06559891. Randomized; triple masking; primary purpose treatment. Start 2024-10-03 (actual); primary completion 2027-03-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 261 participants (planned count; ClinicalTrials.gov record NCT06559891, source copy `cardio:ctgov-nct06559891-2026-09-24`, retrieved 2026-10-26)
- Started: 2024-10-03 (actual) (ClinicalTrials.gov record NCT06559891, source copy `cardio:ctgov-nct06559891-2026-09-24`, retrieved 2026-10-26)
- Primary completion: 2027-03-31 (anticipated) (ClinicalTrials.gov record NCT06559891, source copy `cardio:ctgov-nct06559891-2026-09-24`, retrieved 2026-10-26)
- Completion: 2028-08-15 (anticipated) (ClinicalTrials.gov record NCT06559891, source copy `cardio:ctgov-nct06559891-2026-09-24`, retrieved 2026-10-26)
- Countries: United States; France; Germany; Greece; Italy (ClinicalTrials.gov record NCT06559891, source copy `cardio:ctgov-nct06559891-2026-09-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06559891-2026-09-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
- Acronym: THRIVE
- Condition: Hypertension
- Intervention (Device): TIVUS™ Renal Denervation System
- Intervention (Other): Sham
- Lead sponsor: SoniVie Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: NAMSA
- Collaborator class: OTHER
- Collaborator: European Cardiovascular Research Center
- Collaborator class: NETWORK
- Collaborator: IQVIA Pty Ltd
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as a collaborator: European Cardiovascular Research Center (`cardio:org-european-cardiovascular-research-center`)
- Registry lists this organization as a collaborator: IQVIA Pty Ltd (`cardio:org-iqvia-pty-ltd`)

## Provenance

Content hash: 4f19739b445d821b7af4eb3a1ad8fd88a2167e54c5dcd00802c4aa28df37d3ec
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
